Lenome 10 Capsule contains Lenalidomide 10 mg, an immunomodulatory agent primarily indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. Lenalidomide exerts its therapeutic effects by modulating the immune system, inhibiting angiogenesis, and inducing apoptosis in malignant cells. It is often prescribed as part of combination therapy or as monotherapy depending on the clinical scenario. The capsule should be administered orally, with or without food, as directed by a healthcare professional. Dosage adjustments may be necessary based on renal function and hematologic parameters to minimize adverse effects. Common side effects include neutropenia, thrombocytopenia, fatigue, and gastrointestinal disturbances, necessitating regular monitoring of blood counts and clinical status. Due to its teratogenic potential, Lenome 10 requires strict adherence to pregnancy prevention programs, including effective contraception for both male and female patients during treatment and for a specified period afterward. Patients should be counseled on the importance of avoiding pregnancy and reporting any signs of infection or unusual symptoms promptly. Lenome 10 Capsule should be used under strict medical supervision with appropriate laboratory monitoring to ensure safety and efficacy in managing hematologic malignancies.